Skip to main content
Equibles
TTRX logo

TTRX · Turn Therapeutics Inc.

Track TTRX — free

Use TTRX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about TTRX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$9.46 -0.08 (-0.84%) At close · Aug 21
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Our capital resources may not be sufficient to fund operations through at least the next 12 months from the date that these condensed consolidated financial statements as of June 30, 2026 are issued based on our expected cash needs, which raises substantial doubt about our ability to continue as a going concern.”
View the 10-Q filed Aug 12, 2026
Market Cap
$284.18M
Shares
29.79M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$9.46 Open$9.64 Day$9.35–9.93 Available close range$2.71–10.54 Avg vol 30d74K Short int84K · 0.3% float · 1.0d Short vol49% DataOct 2025–Aug 2026 Filing10-Q · Aug 12

The closing range uses available history since Oct 8, 2025; less than a full year is stored.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 12, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15.1 · calm Equity put/call 0.58
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +88%
above
Price vs 50-day avg +12%
above
RSI (14) 52
neutral
MACD trend Negative
52-week position 86%
near high
Momentum
relative strength
Very Strong
1-month return +11%
trailing
6-month return +158%
trailing
YTD return +140%
this year
Relative strength +147%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $8 › 200d $5 — 50d above 200d
Institutional flow Accumulating
+45% holders QoQ · +11 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.28% of float · ▲ +46.1% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
29 holders — 13F breadth
Squeeze score 54
elevated · 0–100
Fundamentals
Fair
EPS growth −71%
Y/Y
Balance sheet $4.0M
net cash
Quant / Vol
risk profile
Very High
Volatility 111%
annualized · 1-yr
Max drawdown −71%
past year
ATR 8.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 2 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+88% Bullish
Price vs 50-day avg
+12% Bullish
RSI (14)
52 Neutral
MACD trend
Negative Bearish
52-week position
86% Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $8 › 200d $5 — 50d above 200d
Institutional flow Accumulating
+45% holders QoQ · +11 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.28% of float · ▲ +46.1% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
29 holders — 13F breadth
Price context
position in its available closing range
Range low $3 Now $9 · 86% Range high $11
vs 200-day avg +88% vs 50-day avg +12%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
TTRX
Turn Therapeutics Inc.
this stock
$284.18M +140.1% — — 0.3%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $136.93B +20.9% +46.2% 31.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $85.87B +8.1% +20.8% 20.7 3.3%
ARGX
Argenx SE
 $64.56B +23.6% — — 2.1%
CSLLY
Csl Ltd
 $58.31B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
29
% held
3.9%
Net QoQ
+694.2K sh
Top holder
SteelPeak Wealth, LLC
Held Float
View
Held by Funds
Fund positions
4
View
Short & Settlement
Short Interest Rising
Shares short
84.3K
Days to cover
1.0d
Change
+26.6K sh
View
Short Volume
Short vol %
49%
As of
Aug 21, 2026
Short Total
View
Fails to Deliver
FTD shares
5.4K
Value
$42.4K
As of
Jul 28, 2026
View
Off-Exchange
Off-exchange %
48.0%
Week of
Jul 13, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-3.2M
EPS diluted
$-0.12
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 18, 2026
This year
23
View
Earnings & Events
Earnings Calls
Last call
Jun 4, 2026
View

Performance

5D 20D 120D MTD YTD
TTRX -1.2% +10.8% +158.5% +13.2% +140.1%
SPY -1.4% +3.6% +11.6% +2.5% +12.3%
vs SPY +0.2% +7.1% +146.9% +10.7% +127.8%
Key facts CIK 2023016 CUSIP 90021W105 13F (30d) 23 filings 23 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)